Guest guest Posted March 13, 2010 Report Share Posted March 13, 2010 I have just begun participating in a Revlimid and Rituximab experiment for first line treatment. I am 11q deleted but do not have the bulky lymphadenopathy (spelling??) associated with the deletion. I chose to participate in this study with the assumption that if failure occurs, FCR will be as just as effective as it would have been prior to the study. Is there any known reason that this would be an incorrect assumption? TomR Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You are posting as a guest. If you have an account, sign in now to post with your account.
Note: Your post will require moderator approval before it will be visible.